Cancers & treatments·Regimen libraryLater line

Teclistamab

Checked 2026-09-09

Relapsed or refractory myeloma after 3 or more lines including a PI, IMiD and CD38 antibody

One cycle

weekly

7-day cycle, weekly until progression; every 2 weeks after 6 months in complete responseSubcutaneous

Components

Drug	Dose	Route	Days	Note
Teclistamab Bispecific T-cell engager (BCMA×CD3)	step-up 0.06 mg/kg and 0.3 mg/kg, then 1.5 mg/kg weekly	SC	D1	step-up doses 2-4 days apart with inpatient monitoring

Cycles

weekly until progression; every 2 weeks after 6 months in complete response

7-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

CRS in 72% (mostly grade 1-2); infections in 76%: IVIG for hypogammaglobulinaemia, PJP and antiviral prophylaxis.

Used in

Multiple myeloma

Trials

MajesTEC-1 MajesTEC-3

Products

Teclistamab

Source

MajesTEC-1, NEJM 2022

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.